OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
AVTR$8.4358

AVTR.K

Medical Equipment, Supplies & DistributionVerified

The company's capital structure is characterized by a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing. Its liquidity position is marked by a current ratio of 1.78, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -248.8 million USD, which may limit its ability to fund operations and growth without external financing. Profitability metrics reveal a challenging financial situation for AVTR.K. The company reported a net loss of 530.2 million USD and an operating loss of 250.8 million USD, indicating that it is not currently generating positive operating income. The return on equity (ROE) is -9.53%, and the return on assets (ROA) is -4.5%, both of which are significantly below the industry median for the Medical Equipment, Supplies & Distribution sector. AVTR.K's revenue is concentrated in the healthcare services and equipment industry, with no disclosed geographic diversification in the provided data. This concentration may expose the company to specific market risks within the healthcare sector, such as regulatory changes or shifts in demand for medical equipment and supplies. The company's growth trajectory is uncertain, as it is currently reporting a net loss and negative operating income. Analysts have provided a mean price target of 10.04 USD, which is higher than the current market price of 8.43 USD, suggesting some optimism about the company's future performance. However, the company's free cash flow is negative, which may hinder its ability to invest in growth initiatives without additional financing. The risk assessment for AVTR.K indicates a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which may affect its ability to meet short-term obligations. The dilution risk is low, suggesting that the company is not expected to issue a significant number of new shares in the near term. Recent events and filings have not been provided in the input data, so no specific recent developments can be cited for AVTR.K.

30-day price · AVTR+0.89 (+10.8%)
Low$7.42High$9.30Close$9.15As of28 May, 00:00 UTC
Profile
CompanyAVTR.K
TickerAVTR.K
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. AVTR.K operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.

Classification. The company is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

The company's capital structure is characterized by a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing. Its liquidity position is marked by a current ratio of 1.78, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -248.8 million USD, which may limit its ability to fund operations and growth without external financing. Profitability metrics reveal a challenging financial situation for AVTR.K. The company reported a net loss of 530.2 million USD and an operating loss of 250.8 million USD, indicating that it is not currently generating positive operating income. The return on equity (ROE) is -9.53%, and the return on assets (ROA) is -4.5%, both of which are significantly below the industry median for the Medical Equipment, Supplies & Distribution sector. AVTR.K's revenue is concentrated in the healthcare services and equipment industry, with no disclosed geographic diversification in the provided data. This concentration may expose the company to specific market risks within the healthcare sector, such as regulatory changes or shifts in demand for medical equipment and supplies. The company's growth trajectory is uncertain, as it is currently reporting a net loss and negative operating income. Analysts have provided a mean price target of 10.04 USD, which is higher than the current market price of 8.43 USD, suggesting some optimism about the company's future performance. However, the company's free cash flow is negative, which may hinder its ability to invest in growth initiatives without additional financing. The risk assessment for AVTR.K indicates a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which may affect its ability to meet short-term obligations. The dilution risk is low, suggesting that the company is not expected to issue a significant number of new shares in the near term. Recent events and filings have not been provided in the input data, so no specific recent developments can be cited for AVTR.K.
Key takeaways
  • AVTR.K is currently reporting a net loss and negative operating income, indicating a challenging financial situation.
  • The company's liquidity position is moderate, with a current ratio of 1.78, but its free cash flow is negative, which may limit its ability to fund operations and growth.
  • The company's profitability metrics, including ROE and ROA, are significantly below the industry median, suggesting underperformance relative to its peers.
  • Analysts have provided a mean price target of 10.04 USD, which is higher than the current market price, indicating some optimism about the company's future performance.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "The company's margin outlook is negative due to its current net loss and operating loss, which indicate declining profitability.",
  • "rd_outlook_rationale": "No specific information is provided about the company's research and development outlook.",
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$6.55B
Gross profit$2.14B
Operating income-$250.8M
Net income-$530.2M
R&D
SG&A
D&A
SBC
Operating cash flow$623.8M
CapEx-$128.8M
Free cash flow-$248.8M
Total assets$11.79B
Total liabilities$6.23B
Total equity$5.57B
Cash & equivalents$365.4M
Long-term debt$3.95B
Valuation
Market price$8.43
Market cap$5.76B
Enterprise value$9.34B
P/E
Reported non-GAAP P/E
EV/Revenue1.4
EV/Op income
EV/OCF15.0
P/B1.0
P/Tangible book1.0
Tangible book$5.57B
Net cash-$3.58B
Current ratio1.8
Debt/Equity0.7
ROA-4.5%
ROE-9.5%
Cash conversion-1.2%
CapEx/Revenue-2.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricAVTRActivity
Op margin-3.8%3.9% medp25 -31.3% · p75 14.4%below median
Net margin-8.1%2.4% medp25 -30.5% · p75 11.1%below median
Gross margin32.7%46.7% medp25 28.2% · p75 63.1%below median
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-2.0%-4.8% medp25 -11.6% · p75 -2.4%top quartile
Debt / equity71.0%17.9% medp25 2.7% · p75 52.2%top quartile
Observations
IR observations
Mean price target10.04 USD
Median price target9.00 USD
High price target19.00 USD
Low price target7.00 USD
Mean recommendation3.00 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count2.00
Hold count13.00
Sell count2.00
Strong-sell count1.00
Mean EPS estimate0.79 USD
Last actual EPS0.90 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 21:19 UTC#c83c984b
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 10:38 UTCJob: 920b25ae